13+ hour, 46+ min ago   (216+ words) In the first segment of this roundtable series, the panel discusses the current treatment landscape, how it has evolved with new approvals and data, ongoing trials, and what might be on the horizon for patients with ESR1-mutated disease in the…...

2+ day, 8+ hour ago   (38+ words) Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Docwire News Biparatopic HER2 Targeting in Action: Anbenitamab’s Phase 3 Breakthrough Shao ZM, et al. Basch E, et al. 2026 American Society of Clinical Oncology Annual Meeting. Abstract LBA660....

2+ day, 8+ hour ago   (144+ words) Docwire News PHERGain-2: Targeted Therapy Alone Achieves Strong Responses in Early HER2+ Breast Cancer As explained onsite from ESMO Breast Cancer 2026 by Dr. Antonio Llombart-Cussac, PHERGain-2 builds on prior de-escalation research to evaluate a chemotherapy-free, pCR-guided strategy in early HER2-positive breast…...

6+ day, 4+ hour ago   (336+ words) Investigators led by Hope S. Rugo, MD, of City of Hope Comprehensive Cancer Center, recently published safety and patient-reported outcome (PRO) data from TROPION-Breast01 that “complement the improvements in efficacy demonstrated with Dato-DXd versus ICC, supporting Dato-DXd as a treatment option…...

1+ week, 3+ day ago   (306+ words) Outcomes of human epidermal growth factor receptor 2 (HER2)-positive breast cancer have improved significantly alongside the development of new therapies. Even so, biological and clinical heterogeneity continue to create variability in prognosis and treatment sensitivity in early-stage disease, leading to uncertainty…...